Immune checkpoint inhibitors plus chemotherapy for early-stage or locally –advanced triple-negative breast cancer: a systematic review and Bayesian network meta-analysis of randomized trials
Background Immune checkpoint inhibitors (ICIs) combined with chemotherapy have become a cornerstone in managing early and locally advanced triple-negative breast cancer (TNBC). Yet direct comparative evidence on the relative efficacy and safety of different PD-1/PD-L1 agents and treatment strategies—particularly neoadj...